18 results
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
30 Nov 23
Current report (foreign)
6:01am
in the U.S. in prior year, increasing global competitive intensity, and pricing headwinds in EUCAN. In the U.S., ENTYVIO maintains the lead as #1 in both IBD
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
8 Dec 20
Current report (foreign)
6:01am
mg once daily Cohort A: Ponatinib/reduced intensity chemotherapy until progressive disease (PD) or stem cell transplant (SCT) Cohort B: Imatinib … /reduced intensity chemotherapy until PD or SCT Primary endpoint and key secondary endpoint(s) ≤1% BCR-ABL1 at 12 months (time frame: 12 months) Number
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
6 Apr 21
Current report (foreign)
6:29am
significant laboratory values. All TAK-994 TEAEs were mild in intensity. Safety and efficacy findings consistent with previous studies with TAK-925 IV
6-K
TAK
Takeda Pharmaceutical Co
30 Oct 23
Current report (foreign)
6:02am
transmission intensity to maximize the public health impact and minimize any potential risk in seronegative persons.
–The vaccine to be introduced
6-K
TAK
Takeda Pharmaceutical Co
2 Feb 24
Current report (foreign)
6:16am
in settings with high dengue disease burden and high transmission intensity to maximize the public health impact and minimize any potential risk
6-K
EX-99.1
swix glr0km0ht5y
23 Jun 23
Current report (foreign)
6:13am
6-K
EX-99.1
u0qxr3edf rv9x
30 May 23
Current report (foreign)
6:11am
20-F
16g1rgrh0fnm1k370g
27 Jun 19
Annual report (foreign)
6:41am
20FR12B/A
la2mnjb85jk
17 Dec 18
Initial registration of securities (foreign private issuers) (amended)
6:14am
F-4
wzfo1vp9
9 Aug 19
Registration of securities (foreign)
6:27am
F-4/A
4q718doite7l5
12 Nov 19
Registration of securities (foreign) (amended)
9:50am
20FR12B
jxh0gu9dhxrx9ua7w
6 Dec 18
Initial registration of securities (foreign private issuers)
10:39am
DRS/A
71m68flx04swgjnaka
16 Nov 18
Draft registration statement (amended)
12:00am
424B3
1caa53e v7o7xy
14 Nov 19
Prospectus supplement
6:10am
- Prev
- 1
- Next